



RECEIVED

SEP 06 2002

714
P1

Attorney Docket No. 5849.200-US

TECH CENTER 1600/2900 PATENT 112-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka *et al.*

Confirmation No. 6980

Serial No.: 09/533,559

Group Art Unit: 1631

Filed: March 22, 2000

Examiner: J.S. Brusca

For: Methods For Monitoring Multiple Gene Expression

AMENDMENT

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated February 25, 2002, please amend the above-captioned application as follows:

IN THE CLAIMS:

Please cancel claims 1-5, 11-13, 19, 20, 26-28, 34, 40-42, 62, 64, and 65 without prejudice or disclaimer. Please add new claims 90-102 as follows:

90. A method for monitoring differential expression of a plurality of genes in a first filamentous fungal cell relative to expression of the same genes in one or more second filamentous fungal cells, comprising:

(a) adding a mixture of fluorescence-labeled nucleic acids isolated from the filamentous fungal cells to a substrate containing an array of *Aspergillus oryzae* ESTs selected from the group consisting of SEQ ID NOs. 4377-7401, nucleic acid fragments of SEQ ID NOs. 4377-7401, and nucleic acid sequences having at least 90% homology to SEQ ID NOs. 4377-7401, under conditions where the nucleic acids hybridize to complementary sequences of the ESTs in the array, wherein the nucleic acids from the first filamentous fungal cell are labeled with a first fluorescent reporter and the one or more second filamentous fungal cells are labeled with one or more different second fluorescent reporters; and

(b) examining the array by fluorescence under fluorescence excitation conditions wherein the relative expression of the genes in the filamentous fungal cells is determined by the observed fluorescence emission color of each spot in the array in which (i) the fluorescence-labeled nucleic acids obtained from the first filamentous fungal cell

SEP 03 2002

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

SEP 06 2002

TECH CENTER 1600/2900

PATENT

Attorney Docket No. 5849.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka *et al.*

Confirmation No. 6980

Serial No.: 09/533,559

Group Art Unit: 1631

Filed: March 22, 2000

Examiner: J.S. Brusca

For: Methods For Monitoring Multiple Gene Expression

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed **February 25, 2002**.

It is respectfully requested that the time for response to the Office Action dated **February 25, 2002** be extended for a period of **3 months** from **May 25, 2002** to **August 25, 2002**. The required fee for the extension is estimated to be **\$920.00**.

The fee for claims has been calculated as shown below:

Total: $13 - 20 = 0 \times \$18 = \0

Independent: $1 - 3 = 0 \times \$84 = \0

No additional fee for claims is required.

Please charge the required extension and claims fees, estimated to be **\$920.00**, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

09/04/2002 TBESHAH1 00000034 501701 09533559

01 FE:117 920.00 CH

Date: August 23, 2002

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100